Work

Squire: a Randomized, Multicenter, Open-Label, Phase III Study of Gemcitabine-Cisplatin (Gc) Chemotherapy Plus Necitumumab (Imc-11F8/Ly3012211) Vs Gc Alone in the First-Line Treatment of Patients (Pts) with Stage Iv Squamous Non-Small Cell Lung Cancer (Sq-Nsclc): Update on Key Subgroups

Year: 2014

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdu349.11

Authors: M.A. Socinski, L. Paz-Ares, A.V. Luft, A. Szczesna, T.E. Ciuleanu, W. Szafranski, M. Reck, B. Balint, K. Park, C. Schumann, F.R. Hirsch, H. Depenbrock, S. Nanda, N. Chouaki, N. Thatcher

Institutions: University of Pittsburgh, University of Pittsburgh Medical Center, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, Iuliu Hațieganu University of Medicine and Pharmacy, Institute of Oncology Prof. Dr. Ion Chiricuta, LungenClinic Grosshansdorf, Samsung Medical Center, Sungkyunkwan University, University of Colorado Cancer Center, Eli Lilly (Germany), The Christie Hospital, The Christie NHS Foundation Trust

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2252448228

FWCI: 0.535

Cites:

Cited by: 3

Related to: 10